September 24, 2021 5:08pm

It was a chaotic week for the sector and markets

Pre-open indication results: 7 Hits and 0 MISS

Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?

Week in review …

The Dow closed UP +33.18 points (+0.10%); the S&P closed UP +6.50 points (+0.15%) while the Nasdaq closed DOWN -4.54 points (-0.03%)

 

Henry’omics:

Indexes hovered near the flat line Friday, wrapping up a volatile week while the stem, cell and gene therapy sector flubbed its lines and folded down.

Monday started the week in the downside, floated positive for three (3) sessions <Tuesday, Wednesday and Thursday) closed to the downside on Friday.

The Nasdaq is down 0.4% for the week while the Dow +0.05% and S&P +0.3% were up.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Friday opened negative at 5/26, 3 flats and 1 acquired, stayed negative at the mid-day at 10/23, 2 flats, 1 flat and 1 acquired, closing negative at 4/28, 2 flats and 1 acquired;
  • Thursday opened positive at 24/6, 4 flats and 1 acquired, stayed positive at the mid-day at 20/13, 2 flats, 1 flat and 1 acquired, closing positive at 29/5 and 1 acquired;
  • Wednesday opened negative at 14/18, 2 flats and 1 acquired, flipped positive at the mid-day at 18/14, 2 flats and 1 acquired, closing positive at 18/14, 2 flats and 1 acquired;
  • Tuesday opened positive at 29/5 and 1 acquired, stayed positive at the mid-day at 24/8, 2 flats and 1 acquired, closing positive at 22/9, 2 flats and 1 acquired;
  • Monday opened negative at 3/30, 1 flat and 1 acquired, stayed negative at the mid-day at 2/32 and 1 acquired, ending with a negative close of 1/33 and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “the tide is turning. Turning of the tide is a common phrase that references the way the tides are low and high, and the lack of control” … https://www.regmedinvestors.com/articles/12109

 

Pre-open indication results: 7 Hits: < Solid Biosciences (SLDB -$0.29), CRISP Therapeutics (CRSP -$4.82), Editas Medicine (EDIT -$3.36), Global Blood Therapeutics (GBT +$0.95), Applied Genetic Technologies (AGTC -$0.19), Fate Therapeutics (FATE - $4.01), Biostage (BSTG -$0.00)> and 0 MISS>

 

The Biostage (BSTG) Chronicles: “wrongful death law suit, insurance claim denied” … https://www.regmedinvestors.com/articles/12110

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • Net Income: 3 and Net losses: 24

 

Key Metric - volume:

  • Sector volume was LOW with 1 of the 4-upside having higher than the 3-month average volume with Non-Existent volume of 4 of 28-downside having higher than the 3-month average volume;

 

The Biostage (BSTG) Chronicles: wrongful death law suit, insurance claim denied” … https://www.regmedinvestors.com/articles/12110

WHAT happened to the usual “pump/promote”?

Friday closed flat with 62 shares traded after Thursday closed up +$0.06 with 839 shares traded, Wednesday closed down -$0.45 with 3,833 shares traded, Tuesday closed up +$0.25 with 654 shares traded and Monday closed down -$0.26 to $3.40 with 563 shares traded.

  • WERE BSTG’s Q2 8-K and 10-Q filings AUDITED or UNAUDITED for investors?
  • Will legal fees to defend the terminal death suit going to bankrupt the company now, that costs will not be covered by insurance?
  • The largest issue was NOT providing the documents to the other attorneys as a sanction was put-on and then removed?
  • Should the D&O and company and office and board covered insurances <which were very high> about to jump even higher?

 

There are clear winners and losers

Jumping with share pricing momentum:

  • ReNeuron (RENE.L), Alnylam Pharmaceuticals (ALNY) - again, Bellicum Pharmaceuticals (BLCM), Voyager therapeutics (VYGR) to name 4 of the 4 inclining of the 35 covered

Hammered in today’s market:

  • Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), Editas Medicine (EDIT), Ultragenyx (RARE) to name 5 of the 28 declining of the 35 covered

Closing flat:

  • 2 – Biostage (BSTG), Caladrius Biosciences (CLBS) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday the IBB closed down -1.90% and XBI closed down -2.03%
  • Thursday, the IBB closed up +1.35% and XBI closed up +1.88%
  • Wednesday, the IBB closed up +0.02% and XBI closed up +0.28%
  • Tuesday, the IBB closed up +0.97% and XBI closed up +1.16%
  • Monday, the IBB closed down -2.13% and XBI closed down -3.10%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -0.77 points or -4.13% at 17.86
  • Thursday was down -2.24 points or -10.73% at 18.63
  • Wednesday was down -3.49 points or -14.33% at 20.87
  • Tuesday was down -1.29 points or -5.02% at 24.42
  • Monday was up +4.90 points or +23.55% at 25.71

 

September, the third month of Q3/21:

Friday closed negative with 4 advancers, 28 decliners, 2 flats and 1 acquired

Thursday closed positive with 29 advancers, 5 decliners and 1 acquired

Wednesday closed positive with 18 advancers, 14 decliners, 2 flat and 1 acquired

Tuesday closed positive with 22 advancers, 9 decliners, 2 flats and 1 acquired

Monday (9/20) closed negative with 1 advancer, 33 decliners and 1 acquired

 

The week in review …

Pre-open’s:

Monday - RegMed Investors’ (RMi) pre-open: the battle for sentiment lost … https://www.regmedinvestors.com/articles/12101

Tuesday - RegMed Investors’ (RMi) pre-open: the bounce back is here while fear is still on the back burner … https://www.regmedinvestors.com/articles/12103

Wednesday - RegMed Investors’ (RMi) pre-open: consternation versus constipation … https://www.regmedinvestors.com/articles/12105

Thursday - RegMed Investors’ (RMi) pre-open: I have a foreboding feeling coming … https://www.regmedinvestors.com/articles/12107

Friday - RegMed Investors’ (RMi) pre-open: the tide is turning … https://www.regmedinvestors.com/articles/12109

 

Closing bells:

Monday - RegMed Investors’ (RMi) closing bell: The stem, cell and gene therapy sector is vulnerable to extreme market moves, overbought and oversold categories as risk stimulates the susceptibility! … https://www.regmedinvestors.com/articles/12102

Tuesday - RegMed Investors’ (RMi) closing bell: a buying opportunity for the stem cell and gene therapy sector … https://www.regmedinvestors.com/articles/12104

Wednesday - RegMed Investors’ (RMi) closing bell: back in the green after a volatile session … https://www.regmedinvestors.com/articles/12106

Thursday - RegMed Investors’ (RMi) closing bell: lucky sector up day with low volume but, risk is still lurking … https://www.regmedinvestors.com/articles/12108

 

 

The BOTTOM LINE: Today, the sector downsized as the overbought supported by a record high market became oversold as profiteering (which I firmly condone) got a bit overdone.

Investors were still mulling implications on-going political antics. It’s going to “bite” and hard!

Sentiment has been capricious and languishing as the sector bounded to the downside.

The stem, cell and gene therapy sector is still seen as vulnerable to extreme moves in either direction, overbought and oversold categories as risk stimulates the susceptibility!

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.